Trivium Point Advisory’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.27M | Buy |
17,671
+4,570
| +35% | +$535K | 0.21% | 115 |
|
|
2026
Q1 | $1.58M | Sell |
13,101
-2,562
| -16% | -$296K | 0.28% | 87 |
|
|
2025
Q4 | $1.65M | Buy |
15,663
+536
| +4% | +$50.3K | 0.17% | 132 |
|
|
2025
Q3 | $1.27M | Sell |
15,127
-1,181
| -7% | -$97.3K | 0.13% | 151 |
|
|
2025
Q2 | $1.29M | Buy |
16,308
+2,212
| +16% | +$176K | 0.14% | 152 |
|
|
2025
Q1 | $1.27M | Sell |
14,096
-1,209
| -8% | -$113K | 0.16% | 148 |
|
|
2024
Q4 | $1.52M | Buy |
15,305
+1,057
| +7% | +$109K | 0.19% | 132 |
|
|
2024
Q3 | $1.4M | Sell |
14,248
-1,592
| -10% | -$189K | 0.2% | 132 |
|
|
2024
Q2 | $1.96M | Buy |
15,840
+267
| +2% | +$34.4K | 0.29% | 100 |
|
|
2024
Q1 | $2.05M | Sell |
15,573
-1,034
| -6% | -$127K | 0.44% | 67 |
|
|
2023
Q4 | $1.81M | Sell |
16,607
-1,169
| -7% | -$121K | 0.44% | 70 |
|
|
2023
Q3 | $1.81M | Sell |
17,776
-218
| -1% | -$23.5K | 0.5% | 67 |
|
|
2023
Q2 | $2.08M | Sell |
17,994
-4,163
| -19% | -$473K | 0.56% | 63 |
|
|
2023
Q1 | $2.36M | Buy |
22,157
+401
| +2% | +$43.3K | 0.64% | 49 |
|
|
2022
Q4 | $2.5M | Buy |
21,756
+5
| +0% | +$511 | 0.73% | 41 |
|
|
2022
Q3 | $1.9M | Sell |
21,751
-2,563
| -11% | -$229K | 0.59% | 53 |
|
|
2022
Q2 | $2.26M | Sell |
24,314
-490
| -2% | -$43.4K | 0.68% | 44 |
|
|
2022
Q1 | $2.11M | Buy |
24,804
+2,492
| +11% | +$196K | 0.47% | 74 |
|
|
2021
Q4 | $1.71M | Sell |
22,312
-14
| -0.1% | -$1.11K | 0.36% | 91 |
|
|
2021
Q3 | $1.83M | Sell |
22,326
-510
| -2% | -$38.8K | 0.43% | 77 |
|
|
2021
Q2 | $1.78M | Sell |
22,836
-2,287
| -9% | -$170K | 0.44% | 85 |
|
|
2021
Q1 | $1.85M | Sell |
25,123
-1,059
| -4% | -$78.1K | 0.5% | 73 |
|
|
2020
Q4 | $2.1M | Sell |
26,182
-230
| -0.9% | -$17.6K | 0.61% | 49 |
|
|
2020
Q3 | $2.09M | Sell |
26,412
-140
| -0.5% | -$11K | 0.74% | 41 |
|
|
2020
Q2 | $2.02M | Buy |
26,552
+317
| +1% | +$23.9K | 0.8% | 37 |
|
|
2020
Q1 | $2.04M | Sell |
26,235
-866
| -3% | -$68.1K | 1.05% | 29 |
|
|
2019
Q4 | $2.35M | Buy |
27,101
+555
| +2% | +$45.6K | 0.91% | 27 |
|
|
2019
Q3 | $2.13M | Buy |
26,546
+152
| +0.6% | +$12.2K | 0.98% | 28 |
|
|
2019
Q2 | $2.11M | Sell |
26,394
-466
| -2% | -$35.7K | 0.94% | 27 |
|
|
2019
Q1 | $2.13M | Sell |
26,860
-732
| -3% | -$54.7K | 1% | 23 |
|
|
2018
Q4 | $2.01M | Buy |
+27,592
| New | +$1.95M | 1.22% | 16 |
|
Other funds holding MRK
Trivium Point Advisory's MRK Position: Q2 2026 in Review
Trivium Point Advisory increased its Merck (MRK) stake by 35% in Q2 2026, buying an estimated $535K and bringing the position to 17,671 shares worth $2.27M. The position accounts for 0.21% of the portfolio, ranked #115.
Trivium Point Advisory first reported a position in MRK in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.5M in Q4 2022. 3,852 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Trivium Point Advisory held 17,671 shares of Merck worth $2.27M as of Q2 2026.
- Trivium Point Advisory bought 4,570 Merck shares in Q2 2026, an estimated $535K.
- Merck made up 0.21% of Trivium Point Advisory's portfolio in Q2 2026, its #115 holding.
- Trivium Point Advisory first reported a position in Merck in Q4 2018 and has held it in 31 quarters since.
- Trivium Point Advisory's Merck position peaked at $2.5M in Q4 2022.
- 3,852 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.